|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||1.6950 - 1.6950|
|52 Week Range||1.0500 - 2.2500|
|Beta (5Y Monthly)||1.46|
|PE Ratio (TTM)||9.42|
|Earnings Date||Mar 16, 2022 - Mar 21, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.59|
Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or the "Company") today announced that it held its annual and special meeting of shareholders earlier today and that all matters put forward before shareholders for consideration and approval as set out in the Company's management information circular dated May 13, 2022 were approved by the requisite majority of votes cast at the meeting. In particular, shareholders approved the election of all director nominees, the re-approval of Ernst & Young L
Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced its financial and operating results for the three months ended March 31, 2022. Unless otherwise noted, all figures are in U.S. dollars.
Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced that it will release its Q1 2022 financial results on Thursday, May 12, 2022 after market close. The Company will also host a conference call on Friday, May 13, 2022 at 8:30am ET to discuss the results and corporate developments.